Panacea Index Logo

Command Palette

Search for a command to run...

A pilot randomised controlled trial of an online mindfulness-based program for people diagnosed with melanoma.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
July 1, 2019
Lahiru Russell et al. (8 authors)
Journal ArticleRandomized Controlled TrialHuman StudyClinical
Study Details

Study Goal

The researchers aimed to assess the feasibility and acceptability of an online mindfulness-based intervention (MBI) for melanoma survivors and explore its potential benefits on fear of cancer recurrence (FCR), worry, rumination, stress, and mindfulness.

Results Summary

The online MBI was feasible and acceptable, significantly reducing FCR severity compared to the control group, but showed no difference in other outcome measures. Participants valued the program's flexibility and convenience.

Population

People diagnosed with stage 2c or 3 melanoma who had completed treatment.

Effective Dosage

6-week program with short videos, daily guided meditations, and automated email reminders.

Duration

6 weeks

Interactions

None mentioned

Extracted Claims (5)
InterventionDirectionEndpointPopulationDosageImpactClaim #
online mindfulness-based intervention (MBI)
decrease
severity of fear of cancer recurrence (FCR)
people diagnosed with melanoma
mean difference = -2.55; 95% CI -4.43, -0.67; p = 0.008
significantly reduced
#1
online mindfulness-based intervention (MBI)
no change
worry
people diagnosed with melanoma
-
no difference
#2
online mindfulness-based intervention (MBI)
no change
rumination
people diagnosed with melanoma
-
no difference
#3
online mindfulness-based intervention (MBI)
no change
perceived stress
people diagnosed with melanoma
-
no difference
#4
online mindfulness-based intervention (MBI)
no change
trait mindfulness
people diagnosed with melanoma
-
no difference
#5
Abstract

PURPOSE: This study assessed the feasibility and acceptability of an online mindfulness-based intervention (MBI) for people diagnosed with melanoma. The potential benefit of the MBI on fear of cancer recurrence (FCR), worry, rumination, perceived stress and trait mindfulness was also explored. METHODS: Participants who have completed treatment for stage 2c or 3 melanoma were recruited from an outpatient clinic and randomly allocated to either the online MBI (intervention) or usual care (control). The 6-week online MBI comprised short videos, daily guided meditations and automated email reminders. Participants were asked to complete questionnaires at baseline and at 6-week post-randomisation. Study feasibility and acceptability were assessed through recruitment rates, retention and participant feedback. Clinical and psychosocial outcomes were compared between groups using linear mixed models. RESULTS: Sixty-nine (58%) eligible participants were randomised (46 in the intervention; 23 in the control group); mean age was 53.4 (SD 13.1); 54% were female. Study completion rate across both arms was 80%. The intervention was found helpful by 72% of the 32 respondents. The intervention significantly reduced the severity of FCR compared to the control group (mean difference = - 2.55; 95% CI - 4.43, - 0.67; p = 0.008). There was no difference between the intervention and control groups on any of the outcome measures. CONCLUSIONS: This online MBI was feasible and acceptable by people at high risk of melanoma recurrence. It significantly reduced FCR severity in this sample. Patients valued accessing the program at their own pace and convenience. This self-guided intervention has the potential to help survivors cope with emotional difficulties. An adequately powered randomised controlled trial to test study findings is warranted.

Medical Subject Headings (MeSH)
Adaptation, PsychologicalAnxietyCancer SurvivorsFeasibility StudiesFemaleHumansInternetMaleMelanomaMiddle AgedMindfulnessNeoplasm Recurrence, LocalOutcome Assessment, Health CarePilot ProjectsSkin NeoplasmsSurveys and QuestionnairesTelemedicine
Study Links
Quality Scores
SafetyNot Assessed
Efficacy70/10
Quality80/10
Citation Metrics
Total Citations40
Citations/Year6.7
Relative Citation Ratio2.60
NIH Percentile81.7%
Research Impact Scores
APT Score0.95
Weight Score2.39
Normalized Score0.64
Related Supplements